Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system.

Autor: Lombardi Y; Paris Transplant Group, Paris Institute for Transplantation & Organ Regeneration, Inserm/Université Paris Cité, Paris, France; Department of Nephrology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris/Sorbonne University, Paris, France., Raynaud M; Paris Transplant Group, Paris Institute for Transplantation & Organ Regeneration, Inserm/Université Paris Cité, Paris, France., Schatzl M; Department of Medicine III, Medical University of Vienna, Vienna, Austria., Mayer KA; Department of Medicine III, Medical University of Vienna, Vienna, Austria., Diebold M; Department of Medicine III, Medical University of Vienna, Vienna, Austria., Patel UD; Human Immunology Biosciences, Inc. (HI-Bio), South San Francisco, CA, USA., Schrezenmeier E; Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany., Akifova A; Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany., Budde K; Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany., Loupy A; Paris Transplant Group, Paris Institute for Transplantation & Organ Regeneration, Inserm/Université Paris Cité, Paris, France. Electronic address: alexandre.loupy@inserm.fr., Böhmig GA; Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Jazyk: angličtina
Zdroj: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2024 Dec 12. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1016/j.ajt.2024.12.004
Databáze: MEDLINE